Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Identification of selective inhibitors of cdc2-like kinases 1 and 4 (Clk1, Clk4).

Coombs TC, Tanega C, Shen M, Neuenswander B, Porubsky P, Wang JL, Misteli T, Auld DS, Schoenen F, Thomas CJ, Aubé J.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 16 [updated 2013 May 8].

2.

Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.

Coombs TC, Tanega C, Shen M, Wang JL, Auld DS, Gerritz SW, Schoenen FJ, Thomas CJ, Aubé J.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3654-61. doi: 10.1016/j.bmcl.2013.02.096. Epub 2013 Mar 30.

3.

Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).

Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT, Misteli T, Auld DS, Maloney DJ, Thomas CJ.

Bioorg Med Chem Lett. 2011 May 15;21(10):3152-8. doi: 10.1016/j.bmcl.2011.02.114. Epub 2011 Mar 4.

4.

An inhibitor of the Cdc2-like kinase 4 (Clk4).

Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT, Misteli T, Auld DS, Maloney DJ, Thomas CJ.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Mar 29 [updated 2011 Mar 3].

5.

Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.

Schmitt C, Kail D, Mariano M, Empting M, Weber N, Paul T, Hartmann RW, Engel M.

PLoS One. 2014 Mar 27;9(3):e87851. doi: 10.1371/journal.pone.0087851. eCollection 2014.

6.

Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4.

Schmitt C, Miralinaghi P, Mariano M, Hartmann RW, Engel M.

ACS Med Chem Lett. 2014 Jul 14;5(9):963-7. doi: 10.1021/ml500059y. eCollection 2014 Sep 11.

7.

A high-throughput screen for pre-mRNA splicing modulators.

Auld D, Shen M, Thomas C.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2009 May 18 [updated 2010 Sep 2].

8.

Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.

Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P.

Curr Drug Targets. 2014 May;15(5):539-50. Review.

PMID:
24568585
9.

Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.

Jiang K, Patel NA, Watson JE, Apostolatos H, Kleiman E, Hanson O, Hagiwara M, Cooper DR.

Endocrinology. 2009 May;150(5):2087-97. doi: 10.1210/en.2008-0818. Epub 2008 Dec 30.

10.

Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W, Marugan JJ, Inglese J, Austin CP, Misteli T, Auld DS, Thomas CJ.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6700-5. doi: 10.1016/j.bmcl.2009.09.121. Epub 2009 Oct 3.

11.

10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Falke H, Chaikuad A, Becker A, Loaëc N, Lozach O, Abu Jhaisha S, Becker W, Jones PG, Preu L, Baumann K, Knapp S, Meijer L, Kunick C.

J Med Chem. 2015 Apr 9;58(7):3131-43. doi: 10.1021/jm501994d. Epub 2015 Mar 23.

12.

Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.

Labrière C, Lozach O, Blairvacq M, Meijer L, Guillou C.

Eur J Med Chem. 2016 Aug 31;124:920-934. doi: 10.1016/j.ejmech.2016.08.069. [Epub ahead of print]

PMID:
27676471
13.

Manipulation of alternative splicing by a newly developed inhibitor of Clks.

Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, Sumi K, Yomoda J, Murray MV, Kimura H, Furuichi K, Shibuya H, Krainer AR, Suzuki M, Hagiwara M.

J Biol Chem. 2004 Jun 4;279(23):24246-54. Epub 2004 Mar 8.

14.
15.

Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.

Araki S, Dairiki R, Nakayama Y, Murai A, Miyashita R, Iwatani M, Nomura T, Nakanishi O.

PLoS One. 2015 Jan 12;10(1):e0116929. doi: 10.1371/journal.pone.0116929. eCollection 2015.

16.

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.

Rüben K, Wurzlbauer A, Walte A, Sippl W, Bracher F, Becker W.

PLoS One. 2015 Jul 20;10(7):e0132453. doi: 10.1371/journal.pone.0132453. eCollection 2015.

17.

Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.

Bullock AN, Das S, Debreczeni JE, Rellos P, Fedorov O, Niesen FH, Guo K, Papagrigoriou E, Amos AL, Cho S, Turk BE, Ghosh G, Knapp S.

Structure. 2009 Mar 11;17(3):352-62. doi: 10.1016/j.str.2008.12.023.

18.

Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.

Masaki S, Kii I, Sumida Y, Kato-Sumida T, Ogawa Y, Ito N, Nakamura M, Sonamoto R, Kataoka N, Hosoya T, Hagiwara M.

Bioorg Med Chem. 2015 Aug 1;23(15):4434-41. doi: 10.1016/j.bmc.2015.06.018. Epub 2015 Jun 14.

PMID:
26145823
19.

Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.

Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S.

Chem Biol. 2011 Jan 28;18(1):67-76. doi: 10.1016/j.chembiol.2010.11.009.

20.

Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.

Becker W, Joost HG.

Prog Nucleic Acid Res Mol Biol. 1999;62:1-17. Review.

PMID:
9932450
Items per page

Supplemental Content

Write to the Help Desk